Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analyst sentiment is moderately positive: Seven brokerages give Unicycive Therapeutics a consensus “Moderate Buy” rating, with five buys, one hold and one sell. The average 12-month price target is $18.25.
• Shares remain under pressure: UNCY opened at $3.58, down 8%, and trades well below its 50-day and 200-day moving averages of $4.68 and $6.13, respectively. Analysts also expect a full-year loss of approximately $1.16 per share.
• Regulatory and litigation risks are key concerns: Investors face a November 2 deadline to seek lead-plaintiff status in a securities class action alleging insufficient verification of a manufacturer’s progress toward FDA compliance, while earnings-estimate reductions add to the stock’s speculative profile.

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.25.

Several research analysts recently issued reports on UNCY shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th. HC Wainwright cut their target price on Unicycive Therapeutics from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, September 29th. Zacks Research upgraded Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 19th. Wall Street Zen raised Unicycive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Finally, Benchmark reissued a "speculative buy" rating and issued a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Neutral Sentiment: Reported short interest was listed at 0 shares as of October 26, implying no measurable short-position overhang based on the provided data. However, the entry describes this as a large increase, so the figures may be inconsistent.
• Negative Sentiment: Multiple law firms reminded investors of a November 2 deadline to seek lead-plaintiff status in a securities class action covering purchases from December 29, 2025, through June 29, 2026. The repeated alerts increase attention around potential litigation costs, liability, and reputational risk. Glancy Prongay Wolke & Rotter deadline alert
• Negative Sentiment: The allegations center on statements that Unicycive reported its third-party manufacturer had made “significant progress” toward regaining FDA compliance without independently verifying that progress through an inspection. If substantiated, the claims could undermine confidence in the company’s regulatory and manufacturing disclosures. Levi & Korsinsky class-action alert
• Negative Sentiment: Noble Financial brokers reportedly reduced their earnings estimates for Unicycive, adding to concerns about the company’s outlook and reinforcing the stock’s speculative profile.

Institutional Trading of Unicycive Therapeutics

Several institutional investors have recently added to or reduced their stakes in UNCY. Renaissance Technologies LLC acquired a new stake in Unicycive Therapeutics during the 1st quarter valued at approximately $161,000. Bank of America Corp DE lifted its position in shares of Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after purchasing an additional 29,378 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Unicycive Therapeutics in the 2nd quarter worth approximately $248,000. Seven Fleet Capital Management LP acquired a new position in shares of Unicycive Therapeutics in the 1st quarter worth approximately $367,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Unicycive Therapeutics in the 1st quarter worth approximately $940,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Trading Down 8.0%

NASDAQ:UNCY opened at $3.58 on Tuesday. The stock has a market cap of $99.70 million, a P/E ratio of -2.05 and a beta of 1.83. The stock's 50-day moving average is $4.68 and its 200-day moving average is $6.13. Unicycive Therapeutics has a 1-year low of $3.35 and a 1-year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.41. As a group, equities analysts forecast that Unicycive Therapeutics will post -1.16 EPS for the current year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc NASDAQ: UNCY is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company's primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive's lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.